Immuneering Corp Cash Flow-to-Debt Ratio
Immuneering Corp cash flow-to-debt ratio. Immuneering Corp (IMRX) has a Cash Flow-to-Debt Ratio of -0.92x as of September 2025, meaning its operating cash flow of $-11.98 Million could theoretically repay -1% of its total liabilities ($13.08 Million) in one year. See Immuneering Corp (IMRX) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Immuneering Corp (2019–2024)
Cash flow-to-debt ratio of Immuneering Corp from 2019 to 2024. Historical debt coverage capacity for Immuneering Corp across 6 annual periods. Also explore IMRX net asset momentum to track the company's year-over-year net asset growth rate.
Immuneering Corp Cash Flow-to-Debt Ratio by Year (2019–2024)
Immuneering Corp cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Immuneering Corp. For the full cash flow conversion analysis, see IMRX cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.86x | $-55.00 Million | $11.33 Million | ▼ -19.1% |
| 2023 | -4.08x | $-48.97 Million | $12.01 Million | ▼ -15.7% |
| 2022 | -3.52x | $-44.10 Million | $12.52 Million | ▼ -22.5% |
| 2021 | -2.88x | $-30.85 Million | $10.72 Million | ▼ -1098.3% |
| 2020 | -0.24x | $-14.62 Million | $60.90 Million | ▼ -11.5% |
| 2019 | -0.22x | $-4.44 Million | $20.63 Million | — |